G. Deboer

发表

Tamoxifen for early breast cancer: an overview of the randomised trials

Mike Clarke, Luc Bijnens, Michael Gnant, 1998, The Lancet.

Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination

Ellen Warner, Martin J Yaffe, Donald B Plewes, 2004, JAMA.

Cyclical mastopathy and premenopausal breast cancer risk

N. Boyd, P. Goodwin, G. Deboer, 2004, Breast Cancer Research and Treatment.

Urodynamic changes at 18 months post-therapy in patients treated with external beam radiotherapy for prostate carcinoma.

C. Danjoux, G. Deboer, S. Herschorn, 2002, International journal of radiation oncology, biology, physics.

Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma.

Wen Shi, Ian R Wanless, Eiji Miyoshi, 2003, Gastroenterology.

Are serial bone scans useful for the follow‐up of clinically localized, low to intermediate grade prostate cancer managed with watchful observation alone?

L. Klotz, C. Danjoux, G. Deboer, 2003, BJU international.

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Terry L. Smith, R. Collins, L. Holmberg, 1998, Lancet.

Multiple primary squamous cell carcinomas in the upper digestive tract.

G. Deboer, P. Fitzpatrick, B. Tepperman, 1984, International journal of radiation oncology, biology, physics.

Carcinoma of the esophagus. Pretreatment assessment, correlation of radiation treatment parameters with survival, and identification and management of radiation treatment failure

G. Deboer, J. Beatty, W. Rider, 1979, Cancer.

Second primary respiratory tract malignancies in glottic carcinoma

G. Deboer, A. Harwood, D. Bryce, 1980, Cancer.

VP-16 and cisplatin as first-line therapy for small-cell lung cancer.

D. Osoba, G. Deboer, R. Feld, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line therapy with VP-16 and cisplatin for small-cell lung cancer.

D. Osoba, G. Deboer, R. Feld, 1986, Seminars in oncology.

Second primary malignancies following diagnosis of small-cell lung cancer.

M. Lishner, D. Payne, G. Deboer, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective evaluation of quality of life in prostate cancer patients receiving combined treatment of postoperative radiotherapy plus androgen suppression for PT3 or positive resection margin after radical prostatectomy.

P. Cheung, C. Danjoux, E. Szumacher, 2007, European urology.

Effect of combined treatment with salvage radiotherapy plus androgen suppression on quality of life in patients with recurrent prostate cancer after radical prostatectomy.

P. Cheung, C. Danjoux, E. Szumacher, 2006, International journal of radiation oncology, biology, physics.

Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy.

B. Gallie, G. Koren, V. Ling, 1996, Archives of ophthalmology.

Urodynamic findings 3 months after radiotherapy in patients treated with conformal external beam radiotherapy for prostate carcinoma

C. Danjoux, G. Deboer, S. Herschorn, 2002, BJU international.

Temporal trends in breast cancer surgery in Ontario: can one randomized trial make a difference?

Gerrit, C. Naylor, J. Williams, 1994, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma.

V. Ling, H. Yeger, G. Deboer, 1991, The New England journal of medicine.

Cyclophosphamide, doxorubicin, and cisplatin in the treatment of non-small cell bronchogenic carcinoma.

D. Osoba, M. Blackstein, K. Pritchard, 1981, Cancer treatment reports.

Treatment of bone metastases with palliative radiotherapy: patients' treatment preferences.

E. Franssen, E. Szumacher, G. Deboer, 2005, International journal of radiation oncology, biology, physics.

Outcomes of 200 Patients with Localized Prostate Cancer Enrolled in a Watchful Waiting Protocol

L. Klotz, N. Fleshner, G. Deboer, 2002 .

Prognostic factors for small cell carcinoma of the lung.

G. Deboer, R. Feld, U. Sagman, 1988, European journal of cancer & clinical oncology.

Survey of radiation oncologists: practice patterns of the management of stage I seminoma of testis in Canada and a selected group in the United States.

P. Warde, H. Sandler, G. Deboer, 2002, The Canadian journal of urology.

Results of treating Hodgkin's disease without a policy of laparotomy staging.

M. Gospodarowicz, G. Deboer, R. Alison, 1982, Cancer treatment reports.

Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of respon

John M.L. Ebos, Mark Clemons, Robert Buckman, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I-II study of DalCM-P [daily dalteparin (Dal), cyclophosphamide (C) and prednisone (P) and bi-weekly methotrexate (M)] as therapy for metastatic breast cancer (MBC)

R. Kerbel, R. Buckman, M. Clemons, 2005 .

Carcinoembryonic antigen: a useful prognostic marker in small-cell lung cancer.

J. Sculier, G. Deboer, R. Feld, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Herpes zoster in patients with small-cell carcinoma of the lung receiving combined modality treatment.

G. Deboer, R. Feld, W. Evans, 1980, Annals of internal medicine.

Radiotherapy alone in breast cancer. I. Analysis of tumor parameters, tumor dose and local control: the experience of the Gustave-Roussy Institute and the Princess Margaret Hospital.

R. Arriagada, G. Deboer, R. Clark, 1985, International journal of radiation oncology, biology, physics.

Radiotherapy Alone in Breast Cancer: Analysis of Tumor Parameters, Tumor and Lymph Node Doses, Lymph Node Control, Distant Metastasis, and Survival Rates—The Experience of the Gustave‐Roussy Institute and the Princess Margaret Hospital

R. Arriagada, G. Deboer, H. Mouriesse, 1993 .

Effect of androgen suppression on hemoglobin in prostate cancer patients undergoing salvage radiotherapy plus 2-year buserelin acetate for rising PSA after surgery.

P. Cheung, C. Danjoux, E. Szumacher, 2005, International journal of radiation oncology, biology, physics.

The role of serial transrectal ultrasonography in a ‘watchful waiting’ protocol for men with localized prostate cancer

E. Rakovitch, L. Klotz, N. Fleshner, 2001, BJU international.

Symptom control and palliative care content of abstracts presented at the Canadian Association of Radiation Oncologists annual meetings

G. Deboer, E. Chow, E. Barnes, 2004, Supportive Care in Cancer.

How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients?

P. Cheung, C. Danjoux, E. Szumacher, 2005, The Canadian journal of urology.

A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer.

I. Tannock, N. Boyd, N. Boyd, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

VP‐16 alone and in combination with cisplatin in previously treated patients with small cell lung cancer

D. Osoba, G. Deboer, R. Feld, 1984, Cancer.

Does HER2/neu overexpression in breast cancer influence adjuvant chemotherapy and hormonal therapy choices by Ontario physicians? A physician survey

E. Warner, G. Deboer, J. Myers, 2006, Current oncology.

Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.

Neil Fleshner, L. Klotz, N. Fleshner, 2002, The Journal of urology.

PSA doubling time of prostate carcinoma managed with watchful observation alone.

E. Rakovitch, L. Klotz, N. Fleshner, 2001, International journal of radiation oncology, biology, physics.

Ocular involvement in neuroblastoma: prognostic implications.

B. Gallie, G. Deboer, M. Musarella, 1984, Ophthalmology.

Superior vena caval obstruction syndrome in small cell lung cancer

J. Herman, F. Shepherd, J. Sculier, 1986, Cancer.

Hydrogen exchange in photohydrates of cytosine derivatives.

G. Deboer, H. Johns, 1970, Biochimica et biophysica acta.

Neurologic disorders in patients with small cell lung cancer

J. Herman, F. Shepherd, J. Sculier, 1987, Cancer.

Reversal mechanisms for the photohydrates of cytosine and its derivatives.

G. Deboer, O. Klinghoffer, H. Johns, 1970, Biochimica et biophysica acta.

Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma.

L. Klotz, J. Slingerland, J. Tsihlias, 1998, Cancer research.

Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung carcinoma: a prognostic factor independent of Ras.

F. Shepherd, J. Slingerland, C. Catzavelos, 1999, Cancer research.

Multidrug resistance in cancers of childhood: clinical relevance and circumvention.

B. Gallie, V. Ling, G. Deboer, 1993, Advances in pharmacology.

A phase I/II study to evaluate the toxicity and efficacy of accelerated fractionation radiotherapy for the palliation of dysphagia from carcinoma of the oesophagus.

Y. Ung, Z. Kassam, R. Wong, 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).

P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy.

T. Grogan, V. Ling, G. Deboer, 1997, Journal of the National Cancer Institute.

MYCN protein expression as a predictor of neuroblastoma prognosis.

B. Gallie, V. Ling, H. Yeger, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Diagnosis and reversal of multidrug resistance in paediatric cancers.

T. Grogan, B. Gallie, V. Ling, 1996, European journal of cancer.

Multidrug drug resistance in pediatric sarcomas.

V. Ling, G. Deboer, H. Chan, 1995, Hematology/oncology clinics of North America.

Multidrug resistance in pediatric malignancies.

B. Gallie, V. Ling, G. Deboer, 1995, Hematology/oncology clinics of North America.

Multidrug Resistance: Clinical Opportunities in Diagnosis and Circumvention

B. Gallie, V. Ling, G. Deboer, 1994 .

Predictive value of staging investigations in patients with clinical stage I malignant melanoma.

D. Osoba, L. From, G. Deboer, 1987, Plastic and reconstructive surgery.

The value of staging and serial follow‐up investigations in patients with completely resected, primary, cutaneous malignant melanoma

D. Osoba, L. From, G. Deboer, 1985, The British journal of surgery.

Radiotherapy alone in breast cancer. Analysis of tumor and lymph node radiation doses and treatment-related complications. The experience of the Gustave-Roussy Institute and the Princess Margaret Hospital.

R. Arriagada, G. Deboer, R. Clark, 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Wide variation of prostate‐specific antigen doubling time of untreated, clinically localized, low‐to‐intermediate grade, prostate carcinoma

L. Klotz, C. Danjoux, G. Deboer, 2004, BJU international.

Importance of clinical staging in limited small-cell lung cancer: a valuable system to separate prognostic subgroups. The University of Toronto Lung Oncology Group.

R. Ginsberg, G. Deboer, R. Haddad, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intraindividual variation of PSA, free PSA and complexed PSA in a cohort of patients with prostate cancer managed with watchful observation.

L. Klotz, N. Fleshner, C. Danjoux, 2002, Clinical biochemistry.

Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer.

D. Osoba, G. Deboer, R. Feld, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined modality induction therapy without maintenance chemotherapy for small cell carcinoma of the lung.

J. Herman, D. Payne, G. Deboer, 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors in T2 glottic cancer

G. Deboer, A. Harwood, 1980, Cancer.

Combined modality treatment of small cell carcinoma of the lung.

G. Deboer, R. Feld, I. Quirt, 1981, Archives of internal medicine.

Herpes zoster in patients with carcinoma of the lung.

G. Deboer, R. Feld, W. Evans, 1982, The American journal of medicine.

A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: A report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.1

K. Pritchard, G. Deboer, A. Paterson, 1997, Breast Cancer Research and Treatment.

An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer

J. Forbes, J. Ingle, K. Pritchard, 1997, Breast Cancer Research and Treatment.

Combining cyclosporin with chemotherapy controls intraocular retinoblastoma without requiring radiation.

J. O'Brien, B. Gallie, G. Koren, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Is bone marrow examination in small-cell lung cancer really necessary?

G. Deboer, R. Feld, I. Quirt, 1986, Annals of internal medicine.

SURVEY: HER2 AND ADJUVANT BREAST CANCER TREATMENT

E. Warner, G. Deboer, J. Myers, 2022 .

Individualized planning target volumes for intrafraction motion during hypofractionated intensity-modulated radiotherapy boost for prostate cancer.

D Andrew Loblaw, Jean-Philippe Pignol, Patrick Cheung, 2005, International journal of radiation oncology, biology, physics.

The prognostic significance of pretreatment serum lactate dehydrogenase in patients with small-cell lung cancer.

D. Payne, G. Deboer, R. Feld, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not?

L. Klotz, C. Danjoux, G. Deboer, 2002, International journal of radiation oncology, biology, physics.

Prognostic factors in T3 glottic cancer

F. Kazim, G. Deboer, A. Harwood, 1981, Cancer.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Y Wang, Mike Clarke, Donald A. Berry, 2005, The Lancet.

Invasive squamous cell carcinoma of the vulva: defining low and high risk groups for recurrence

T. Colgan, G. Deboer, G. Thomas, 1990, International Journal of Gynecologic Cancer.

(IN)-efficacy of salvage radiotherapy for rising PSA or clinically isolated local recurrence after radical prostatectomy.

C. Danjoux, G. Deboer, Julie J. Hong, 2002, International journal of radiation oncology, biology, physics.

Limited efficacy of salvage radiotherapy for biopsy confirmed or clinically palpable local recurrence of prostate carcinoma after surgery.

C. Danjoux, E. Szumacher, G. Deboer, 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Superior vena caval obstruction syndrome in small cell lung cancer

J. Herman, F. Shepherd, J. Sculier, 1986, Cancer.

Reduction in local recurrence and improved survival in surgically treated patients with small cell lung cancer.

R. Ginsberg, F. Shepherd, J. Cooper, 1983, The Journal of thoracic and cardiovascular surgery.

5‐Fluorouracil, Adriamycin, and Mitomycin‐C (FAM) in the Treatment of Inoperable Adenocarcinoma of the Lung

G. Deboer, R. Burkes, F. Shepherd, 1986, American journal of clinical oncology.

Serial free/total prostate specific antigen ratios over time in clinically localized prostate cancer managed with watchful observation alone

L. Klotz, N. Fleshner, C. Danjoux, 2001 .

2151 Watchful observation of asymptomatic, favorable grade, prostate carcinoma with selective delayed intervention based on PSA, histologic, and/or clinical progression

E. Rakovitch, L. Klotz, N. Fleshner, 1999 .

R. Kerbel, R. Buckman, J. Slingerland, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Limitations of urinary mutagen assays for monitoring occupational exposure to antineoplastic drugs.

C. Erlichman, G. Deboer, P. Tuffnell, 1986, American journal of hospital pharmacy.

How does histologic grade change over time on repeat biopsy in untreated, favorable grade, localized prostate cancer

L. Klotz, N. Fleshner, L. Kapusta, 2001 .